Prothena (PRTA) Q3 2026 earnings review
Prothena cuts its cash burn, but contracted revenue hits zero
Prothena, a biotechnology group developing antibodies for brain and heart diseases, brought its quarterly cash burn down as last year's layoff costs faded. Third-quarter cash used in operations and investing fell to $12 million while the net loss narrowed to $17 million. Chief executive Gene Kinney highlighted partner Novo Nordisk's new heart study data and held the full-year outlook steady, which by our math implies about $12 million of cash burn in the fourth quarter.
| Q3 net cash burn | $12.0M down from $25.7M in Q2 and $40.6M a year ago |
|---|---|
| Q3 net loss | $16.5M narrowed from $36.5M a year ago |
| Ending cash and restricted cash | $272.2M zero debt; $0 deferred revenue left |
| Full-year 2026 outlook | Unchanged $18–23M cash burn; ~$259M year-end cash |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because lower spending is offset by a dry near-term revenue pipeline and long waits for partner trials. On the positive side, third-quarter net loss came in smaller than what the company's own second-half plan pointed to, proving the cost cuts are sticking. One caution: finishing its Phase 1 contract work for Bristol Myers Squibb drained deferred revenue to zero, and the release gave no update on a potential $55 million year-end payout for that drug.
The question now is whether Prothena can turn its early lab technology into a paid partnership before its $272 million cash pile is tapped to fund new human trials. Supporters see the 12-to-24-month partner tests on its cell-delivery tool as a free path to new deals, while skeptics see an early-stage project that will require heavy internal spending while big Phase 3 readouts sit out in 2029. Bristol Myers Squibb's pending decision on advancing PRX019 by year-end 2026 and its Alzheimer's readout in the first half of 2027 will test the partner model first.
🐂 Bull Case
Partner Trials Advance as Novo Adds Heart Data
Prothena relies on big pharmaceutical partners to fund and run late-stage clinical trials for the drugs it discovered. Chief executive Gene Kinney noted that Novo Nordisk presented a follow-up analysis from its Phase 2 study of coramitug, an antibody for heart disease caused by transthyretin protein buildup (ATTR-CM).
The analysis looked at high-sensitivity C-reactive protein (hsCRP), a blood marker for inflammation. Kinney said the data showed "that the inflammatory biomarker hsCRP decreased from baseline in patients treated with coramitug, while increasing in those receiving placebo", which he added was "further supporting coramitug’s potential as an amyloid-depleting treatment for ATTR-CM".
- Coramitug inflammation marker: down about 8% at week 52, while placebo rose about 33%
- Partner payments received to date: $650 million across all partnered drugs
- Remaining milestone potential: over $2.25 billion, plus future sales royalties
What to watch: Phase 2 trial results in the first half of 2027 for moponetug, an Alzheimer's drug partnered with Bristol Myers Squibb. Positive data would trigger the next stage of development and bring Prothena closer to a milestone payout.
Cost Reset Cut Quarterly Cash Burn to $12M
After stopping work on its lead drug birtamimab last year, the Irish biotech group cut staff and handed late-stage trial costs to partners. That overhaul showed up in full during the third quarter as severance payments wound down.
Net cash used in operating and investing activities dropped to $12.0 million, down from $25.7 million in the second quarter and $40.6 million a year ago. Research and development spending fell 71% from a year ago to $8.4 million, which Prothena said was "primarily due to lower clinical trial expenses, lower personnel expenses and lower consulting expenses".
Because the third-quarter net loss of $16.5 million beat the pace implied by the full-year outlook, the company has a wide buffer for the fourth quarter. By our math, the unchanged annual plan leaves room for a $25.1 million net loss in the final three months.
What to watch: full-year cash burn in the 2026 annual report, along with the initial spending plan for 2027. Keeping quarterly operating cash use near $12 million without partner payments would preserve the cash pile through the 2027 Alzheimer's readout.
🐻 Bear Case
Contracted Revenue Reached Zero After Q3
Outside of one-off milestone checks when a partner starts or finishes a study, Prothena collects collaboration revenue by finishing early trial work for Bristol Myers Squibb. In the third quarter, revenue fell 74% from a year ago to $0.6 million from the "partial performance of our PRX019 Phase 1 clinical trial obligation".
Recognizing that $0.6 million drained the remaining deferred revenue balance on the balance sheet from $0.6 million in June down to zero. With that contract finished, the biotechnology firm has no contracted revenue left to book in the fourth quarter.
Future revenue now depends entirely on partner decisions. Prothena previously noted it could earn a $55 million milestone payment in 2026 if Bristol Myers Squibb advances PRX019, a drug candidate for neurodegenerative disease, after Phase 1. Today's release did not mention PRX019 in its pipeline highlights.
What to watch: any decision from Bristol Myers Squibb on advancing PRX019 by the end of 2026. If the partner declines to move the drug into Phase 2 or delays the choice, Prothena misses a $55 million cash injection.
Partner Timelines and Early Lab Work Stretch to 2029
Prothena is pitching its wholly owned preclinical programs and its CYTOPE platform, a tool designed to deliver drugs inside cells, as its next growth engine. Kinney stated that "we continue to evaluate our proprietary CYTOPE ® technology with industry partners through multiple research collaborations over the next 12 to 24 months".
That timeline cuts against the idea of a near-term deal. One to two years of evaluation means these research collaborations are early tests with no disclosed upfront payments, leaving every wholly owned drug candidate—including TDP-43 CYTOPE for ALS and PRX012-TfR for Alzheimer's—in preclinical lab testing rather than human trials.
Meanwhile, the two biggest partnered programs—Roche's prasinezumab for Parkinson's disease and Novo's coramitug for heart disease—will not finish their Phase 3 trials until 2029. The company also dropped earlier mentions of over $3 billion in future milestones down to $2.25 billion.
What to watch: any signed licensing agreement with disclosed upfront cash for CYTOPE or PRX012-TfR during 2027. Without a commercial partner paying for human trials, Prothena will have to spend its own cash to move its lab programs into the clinic.
Buyback Pace Slowed Alongside Cash Reserves
Supporters view Prothena's share buyback as a smart way to return excess cash while waiting for partner payouts, and the program has cut the average share count by 4.4% over the past year. Critics counter that spending cash on buybacks weakens the balance sheet before the company knows how much its own lab drugs will cost to test in humans.
In the third quarter, the drug developer bought back 501,492 shares. By our math, subtracting first-half buyback spending of $22.3 million from the nine-month total of $26.6 million leaves $4.3 million spent in Q3 at an average price of $8.57 per share, down from $15.0 million spent in Q2.
With the $100 million authorization expiring on December 31, 2026, Prothena has used just over a quarter of the headline figure. What to watch: fourth-quarter buyback spending and whether the board renews the program for 2027, which will show if preserving cash has overtaken share reductions.
💲 Other KPIs
Total cash and restricted cash declined 5.8% from $289.1 million at the end of June and from $308.4 million at the end of 2025. The company carries no debt. The $16.8 million quarterly drop matched the $12.0 million operating and investing cash burn plus $4.3 million in share buybacks.
Overhead and administrative spending fell 20.0% from $13.2 million a year ago and edged down from $10.9 million in Q2 on lower staff and consulting bills. Even after the cuts, administrative costs exceeded the $8.4 million spent on research and development, and included $4.6 million in non-cash stock pay.
Unpaid severance and contract-exit bills on the balance sheet are down 95.6% from $13.3 million at the end of 2025. However, the balance ticked up slightly from $0.35 million in June as Prothena booked $0.42 million in new third-quarter restructuring charges, showing the wind-down has a small lingering tail.
🔮 Guidance
Unchanged. Prothena still expects to burn $20.5 million at the middle of the range for the full year, boosted by Novo's $50 million payment in Q1. With $8.9 million used across the first nine months, by our math the plan implies $11.6 million of cash burn in Q4, matching Q3's $12.0 million pace.
Unchanged. The full-year forecast still calls for a net loss of $27.5 million at the middle of the range, including about $26 million in non-cash stock compensation. Because the nine-month net loss is only $2.4 million, by our math the outlook leaves room for a $25.1 million loss in Q4 against Q3's $16.5 million loss.
Unchanged. The biotech group still expects to finish December with about $259 million in total cash before any additional fourth-quarter share buybacks. From September's $272.2 million balance, by our math that target builds in a $13.2 million fourth-quarter cash drain, consistent with the $11.6 million implied operating burn.
❓ Key Questions
Will Bristol Myers Squibb advance PRX019 this year?
Prothena finished its Phase 1 contract work on PRX019 in Q3, draining deferred revenue to zero, and dropped the drug from its pipeline highlights. A partner decision to start Phase 2 was expected by year-end 2026 and carries a $55 million milestone payment.
Why did potential partner milestones drop to $2.25 billion?
Previous releases stated Prothena could receive up to $3 billion in future clinical, regulatory, and sales milestone payments across its partnered programs. Today's commentary cited over $2.25 billion remaining, leaving a roughly $750 million reduction unexplained.
Why does the outlook imply a $25M Q4 loss?
Nine-month net loss sits at $2.4 million after a $16.5 million loss in Q3, yet the unchanged $25–30 million full-year loss outlook implies a $25.1 million fourth-quarter loss by our math. Investors need to know if Q4 carries higher lab spending.
Who is filling the chief financial officer role?
The company has not held an earnings call or listed its finance chief, chief development officer, or chief operating officer in its materials since early 2026. Management has still not clarified its senior executive roster after last year's layoffs.